Faculty Members

Prof.Sanaa Moharram Moharram Kamal

Doctorate in Medicine Professor Department of Internal Diseases College of Medicine In Al Karj

Kharj
011-588-6633
s.kamal@psau.edu.sa

Curriculum Vitae
Publications

Education

1993: Doctorate from Ain Shams University, Cairo Egypt 1987: Master in Medicine, Ain Shams University, Cairo Egypt 1983: M.B.Bch in Medicine and Surgery< Ain Shams University, Cairo, Egypt 2009: Certificate in Infections in Complex Humanitarian Disasters from Boston University, Boston, MA, USA 2010: Certificate in Pandemics from MIT, Cambridge, MA, USA 2012: Master in Bio statistics and Public health from the University of Liverpool, UK

Research Interests

Gastroenterology: Viral hepatitis, NAFLD/NASH, Inflammatory bowel disease
Infectious diseases: COVID-19, GIT infections, HIV

Experience

2012 - until now - Professor of Medicine - Prince Sattam Bin Abdulaziz College of Medicine
2002 - until now - Professor of Medicine - Ain Shams University
2006 - 2009 - Adjunst Professor - New York Scholl of Medicine
2000 - 2005 - Associate Professor/Visting Professor - Harvard Medical School, Boston, MA, USA
1999 - 2000 - Visiting Faculty - National Institutes of Health, MD, USA
1996 - 1999 - Post-doctor - College of Medicine, University of Freiburg, Germany

Responsibilities

1. Teaching 2. Clinical training 3. Medical Research 4. Consultant of Medicine at PSAU Hospital 5. Coordinator of Development and Quality for the College of Medicine, PSAU 6. Consultant of Quality at the Deanship of Development and Quality, PSAU

Publications

1. AlArjani A, Nasseef MT, Kamal SM, Rao BVS, Mahmud M, Uddin MS. Application of Mathematical Modeling in Prediction of COVID-19 Transmission Dynamics.
Application of Mathematical Modeling in Prediction of COVID-19 Transmission Dynamics. Arab J Sci Eng. 2022 Jan 7:1-24. doi: 10.1007/s13369-021-06419-4.
2.Kamal S, Naghib MM, Al Zahrani J, Hassan H, Moawad K, Arrahman O Influence of Nutrition on Disease Severity and Health-related Quality of Life in Adults with Sickle Cell Disease: A Prospective Study. Mediterr J Hematol Infect Dis. 2021 Jan 1;13(1):e2021007. doi: 10.4084/MJHID.2021.007. eCollection 2021
3. Kamal S, Abdelhakam S, Ghoraba D, Massoud Y, Aziz KA, Hassan H, Hafez T, Abdel Sallam AThe frequency, clinical course, and health related quality of life in adults with Gilbert's syndrome: a longitudinal study. BMC Gastroenterol. 2019 Feb 4;19(1):22. doi: 10.1186/s12876-019-0931-2. PMID: 30717703
4. Kamal S, Abdelhakam S, Ghoraba D, Mohsen MA, Salam AA, Hassan H, Nabeigh L. .The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study Mediterr J Hematol Infect Dis. 2019 Nov 1;11(1):e2019060. doi: 10.4084/MJHID.2019.060. eCollection 2019
5. Kamal S, Aldossari KK, Ghoraba D, Abdelhakam SM, Kamal AH, Bedewi M, Nabegh L, Bahnasy K, Hafez T.
Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. BMJ Open Gastroenterol. 2018 Jan 29;5(1):e000150. doi: 10.1136/bmjgast-2017-000150. eCollection 2018.
6. Kamal SM. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.
. Hepat Med. 2014 Jun 24;6:61-77. doi: 10.2147/HMER.S41127. eCollection 2014. PMID: 25114601 Free PMC article. Review.
7. Kamal SM5. Hepatitis .C virus genotype 4 therapy: progress and challenges.
Liver Int. 2011 Jan;31 Suppl 1:45-52. doi: 10.1111/j.1478-3231.2010.02385.x. PMID: 21205137 Review.
8. Kamal SM, Nasser IA Hepatitis C genotype 4: What we know and what we don't yet know.
. Hepatology. 2008 Apr;47(4):1371-83. doi: 10.1002/hep.22127. PMID: 18240152 Review.
9. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.
10. Kamal SM. Acute hepatitis C: prospects and challenges. . World J Gastroenterol. 2007 Dec 28;13(48):6455-7. doi: 10.3748/wjg.v13.i48.6455. PMID: 18161913
11. Bedewi MA, Abodonya A, Kotb M, Kamal S, Mahmoud G, Aldossari K, Alqabbani A, Swify S Estimation of ultrasound reference values for the lower limb peripheral nerves in adults: A cross-sectional study. Medicine (Baltimore). 2018 Mar;97(12):e0179. doi: 10.1097/MD.0000000000010179. PMID: 29561431 Free PMC article.
12. Bedewi MA, Abodonya A, Kotb M, Mahmoud G, Kamal S, Alqabbani A, Alhariqi B, Alanazy MH, Aldossari K, Swify S, Al-Bader F. Estimation of ultrasound reference values for the upper limb peripheral nerves in adults: A cross-sectional study. Medicine (Baltimore). 2017 Dec;96(50):e9306. doi: 10.1097/MD.0000000000009306. PMID: 29390395 Free PMC article.
13 Kamal SM, Mahmoud S, Hafez T, El-Fouly R Viral hepatitis a to e in South mediterranean countries.. Mediterr J Hematol Infect Dis. 2010 Feb 10;2(1):e2010001. doi: 10.4084/MJHID.2010.001. PMID: 21415943. Liver Int. 2010 Mar;30(3):342-55. doi: 10.1111/j.1478-3231.2009.02188.x. Epub 2009 Dec 10. PMID: 20015149 Review.
14. Kamal SM. Am J Gastroenterol. 2009. Improving outcome in patients with hepatitis C virus genotype 4.
7 Nov;102(11):2582-8. doi: 10.1111/j.1572-0241.2007.01538.x. Epub 2007 Sep 26.
11. Transient Elastography and Non-invasive Fibrosis Markers in Chronic Hepatitis C without and with Schistosomiasis. Sanaa Kamal, Samar Kassem, Amany Ahmed, Mohamed Omar, Sara Mahmoud, Tamer Hafez, American Journal of Gastroenterology (2017 in press)
12. Cyanocobalamin, vitamin D and Ferritin Levels in Saudi Patients with Non-alcoholic Liver Disease (NAFLD) Sanaa M. Kamal, Waheed M. A. Al-Harizi, Magdy Saad, Mohamed A. Bedewi. Liver International accepted May ,2017
13. Impact of Helicobacter Pylori eradication on Vitamin B12 and Vitamin D levels. Sanaa M. Kamal, Waheed Al Harizi, Shafqat Qamar, Magdy Saad. Helicobacter accepted May ,2017
14. Comparison of immunogenicity and safety of Engerix B and Twinrix vaccine in aSaudi Population. Sanaa M. Kamal, Abdul Rahaman Aldiab, Shafqat Qamar, Waheed Al Harizi. Gut. accepted May ,2014
15. Pegylated Interferon α-2a and Pegylated Interferon α-2b plus Ribavirin in Chronic HCV Genotype 4: A randomized trial and quality of life analysis" Sanaa Kamal, Amany Ibrahiem, Tamer Hafez; Isa Obedan I; Sara Mahmoud, Mona Motaoe, Dahlia Ghoraba, Ahmed Abdel Aziz. Liver Int. 2011;31(3):401-411. 6.
16. Hepatitis C virus genotype 4 therapy: progress and challenges Kamal SM. Liver Int. 2011 J;31 Suppl 1:45-52
17. Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine. Sanaa Kamal. Current
Pharmacogenomics and Personalized Medicine 2011. 8 (5): 333-342
12. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P Liver Int. 2010 Mar;30(3):342-55
13. Pegylated Interferon α-2a and Pegylated Interferon α-2b plus Ribavirin in Chronic HCV Genotype 4: A randomized trial and quality of life analysis" Sanaa Kamal, Amany Ibrahiem, Tamer Hafez; Isa Obedan I; Sara Mahmoud, Mona Motaoe, Dahlia Ghoraba, Ahmed Abdel Aziz. Liver Int. 2011;31(3):401-411.
14. Hepatitis C virus genotype 4 therapy: progress and challenges Kamal SM. Liver Int. 2011 J;31 Suppl 1:45-52
15. Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine. Sanaa Kamal. Current
Pharmacogenomics and Personalized Medicine 2011. 8 (5): 333-342
16. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Antaki N, Craxi A, Kamal S, Moucari R, Van der
Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P Liver Int. 2010 Mar;30(3):342-55
17. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Sanaa Kamal. Liver International, Liver Int. 2009 Jan;29
Suppl 1:39-48
18. Acute Hepatitis C. A systematic review. Sanaa Kamal. Am J Gastroenterol. 2008 May;103(5):1283-97
19. Hepatitis C genotype 4: What we know and what we don’t yet know. Sanaa Kamal and Imad Nasser. Hepatology. 2008 Jan 28;47(4):1371-1383.
20. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response.
Kamal S; Kamary S; Shardell M; Nasser I; Hashem M; Muhamadi M; Moustafa A; Sayed K; Abdel Hakem S; Ibrahim A; Mansour H; Abddelaziz M. Hepatology. 2007 Dec;46(6):1732-40.
21. Acute hepatitis C: Prospects and challenges. Kamal SM.. World J Gastroenterol. 2007 Dec 28;13(48):6455-7.
22. Genotypic variation around the world: Is hepatitis C evolving? Sanaa M. Kamal, Current Hepatitis Reports 2006
23. Improving Outcome in Patients with Hepatitis C Virus Genotype 4. Sanaa M. Kamal. Am J Gastroenterol. 2007 Nov;102(11):2582-8.
Epub 2007 Sep 26
24. Progression of Fibrosis in Chronic Hepatitis C with and without Schistosomiasis: Correlation to Serum Fibrosis Markers and Cytokines..Kamal S, Turner B, Bianch L; Tawil A, Ahmed N ,Mahmoud M ; Koziel M;, Afdhal N, Hepatology, Vol. 43, No. 4, 2006
25. Peg-interferon alfa-2b for the treatment of patients with acute hepatitis C: Impact of onset of therapy on sustained virologic response Kamal S, El
Tawil A., EL Naggar K, Rasenack J, Hakam S, Saleh W, EL Fouly, Ismail A, Abdel Aziz A, Madwar M, Koziel M, Afdhal N.Gastroenterology
2006;130:632–638
26. Duration of Peg-interferon alfa-2b in acute hepatitis C: A randomized clinical trial.S Kamal, K El Naggar, J Chen, M Moniem, I Gohary, N Afdhal; Jens Rasenack. Hepatology, HEPATOLOGY, Vol. 43, No. 5, 2006
27. Immune modulation by helminthic infections: worms and viral infections. S. M. K Kamal and E Khalifa.. Parasite Immunology :365-3024.2006.
28. Peginterferon-alpha 2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virologic response. Kamal S, El Tawil A., Nakano T, Rasenack J, Hakam S, Saleh W, Ismail A, Abdel Aziz A, Madwar M. GUT, 2005 Gut 54 (6): 858-866
29. Cellular Immune Responses in Seronegative Sexual Contacts of Acute Hepatitis C Patients . Sanaa M Kamal , Mahmoud Massoud, Jens Rasenack,
, ,
Thomas Peters, Camilla S. Graham, Qi He Ahmed Al Tawil Leonardo Bianchi, Tatsarouni Nakano, Betty Robertson, Alaa Ismail Margaret James
,
.
Koziel J Virol. 2004 Nov;78(22):12252-8.
*
30. Peginterferon Alpha Therapy in Acute Hepatitis C Prevents Chronicity and Enhances Hepatitis C Virus-Specific T-cell Responses. Sanaa M Kamal ,
, ,
Alaa Ismail, Camilla S Graham, Qi He, Jens W Rasenack Thomas Peters Ahmed A Tawil, Jutta J Fehr Khalifa El Sayed Khalifa, Mahmoud M
.
Massoud, Margaret J Koziel
Hepatology. 2004 Jun;39(6):1721-31.
+
31. Kinetics of intrahepatic hepatitis C-virus specific CD4
T cell responses in patients coinfected with S.mansoni: Relation to liver fibrosis progression.
,
Sanaa M Kamal, Camilla A Graham, Qi He, Leonardo Bianchi, Jens W Rasenack Ahmed A Tawil Khalifa A Khalifa, Mahmoud M Massoud, Alaa
Ismail, Margaret J Koziel. Journal of Infectious Diseases The Journal of Infectious Diseases 2004; 189:1140–50
32. Peginterferon Alone or in Combination with Ribavirin Enhances HCV Specific CD4+ T Helper 1 Responses in Patients with Chronic Hepatitis C.
Sanaa M. Kamal; Jutta Fehr, Bernd Roesler, Thomas Peters, Jens W. Rasenack. Gastroenterology 2002; 123 (4)
33. Acute Hepatitis C With and Without Schistosomiasis: Correlation with Hepatitis C Specific CD4+ T Cell and Cytokine Response. . Kamal S, Rasenack J, Bianchi L, Al Tawil A, Mansour H, Khalifa K, Peters T, Koziel M. Gastroenterology. 2001 Sep;121(3):646-56.
34. Specific cellular immune response and cytokine profile in patients with chronic hepatitis C co-infected with schistosomiasis. Kamal SM, Bianchi L, El
Tawil A, Koziel M, Khalifa K, Peters T, Rasenack J. Journal of Infectious Diseases 2001; 184:972-982
35. Interferon therapy in patients with hepatitis C and schistosomiasis. Kamal SM, Madwar MA, Peters T, Fawzy R, , Rasenack J. J Hepatol. 2000 Jan;
32(1):172-4.
36. Clinical, Virological, Histological Featurres and Long Follow-up of Patients with Hepatitis C Co-infected with Schistosomiasis. Kamal SM, Madwar
MA, Bianchi L, Peters T, Fawzy R, El Tawil A, Rasenack J. Liver. 2000 Jul; 20(4):281-9
37. The diagnostic significance of ascitic fluid ferritin. Kamal SM, Farrag D, Skr MA, Abdel Ghany EA. Egyptian Journal of Medical Laboratory Science
1999; 4: 9-16.
38. The effect of diuresis on the opsonic activity of cirrhotic patients. Abdel Moneif W, Kamal SM, Sherif H. Egypt J Med Lab Sci 1999; 4: 39-44.
39. Renal Hemodynamics alterations in hepatic cirrhosis evaluated by duplex Doppler ultrasound. Kamal SM, Omar OH, El Naggar MK. Journal of
Hepatology, Gastroenterology and Infectious Diseases (JHGID) 1996; 4 (3): 79-85.
40. The diagnostic significance of ascitic fluid ferritin. Kamal SM, Farrag D, Skr MA, Abdel Ghany EA. Egyptian Journal of Medical Laboratory Science
1995; 4: 9-16.
41. The effect of diuresis on the opsonic activity of cirrhotic patients. Abdel Moneif W, Kamal SM, Sherif H. Egypt J Med Lab Sci 1995; 4: 39-44.
42. Allergic manifestations of giardiasis. Kamal SM, Abbass M, El Sherif H. Journal of Tropical Medicine 1996, 4: 55-60.
43 Cryoglobulinemia in chronic viral hepatitis. Kamal SM, Ezzat A, Shaker A, El Nokaly F. Egypt J Med Lab Sci 1996; 5 (1): 21-28.
44. Parasitological and bacteriological studies in recurrent diarrhoea in patients with chronic liver diseases. Younes TA, Hussein MM, Kamal SM, Mahmoud DM, Metwaly SF. J Egypt Soc Parasitol. 1996 Dec;26(3):697-708.
45. Colorectal cancer in Egyptian patients under 40 years of age. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S, Hammam HM, el- Hattab OH, Kamal SM, Soliman AG, Dorgham LA, McPherson RS, Beasley RP. Int J Cancer. 1997 Mar 28;71(1):26-30.
46. Correlation between p53 expression and the clinicopathologic and DNA ploidy patterns in different forms of colitis in Egypt. Massoud MA, Kamal
st
SM, Eissa S, Khalifa EK. Ismail N. Journal of Gastrointestinal tract in the 21
Century 1997; 2 (2):62-69.
47. The prevalence of hepatitis E virus among acute sporadic hepatitis patients in Cairo. Madwar MA, Kamal SM, Ezzat A, Talkhan H, Sultan Y. Journal of Immunology 1997; 4: 38-44.
48. Renal Hemodynamics alterations in hepatic cirrhosis evaluated by duplex Doppler ultrasound. Kamal SM, Omar OH, El Naggar MK. Journal of
Hepatology, Gastroenterology and Infectious Diseases (JHGID) 1998; 4 (3): 79-85.
49. Serum nitrite and nitrate in cirrhotic patients: Relation to endotoxemia and cytokines. Kamal SM, Abdel Monseif W, Nessim N, Nooh O, Madwar
MA. Journal of Hepatology, Gastroenterology and Infectious Diseases (JHGID) 1998; 4 (4): 39- 48.
50. Lymphadenopathies of undetermined etiology in Egypt. Abdel Wahab MF, Saif El Din, Kamal SM, El Tawil AA, Azab ME. Egyptian Medical
Journal (EMJ) 1992; 6 (2): 121-127
57. The role of Epestein Barr virus in Hodgkin Disease. El Okbi SA, Kamal SM, Talkhan HS. Journal of Immunology 1993; 1: 78-81.
58. Helicobacter pylori infection in gastric malignancy. Abdel Monseif W, Kamal SM, Azzazy H, Ismail S, Ezz El Din W. Menoufia Med. Journal 1993;
6: 193-196.
59. Alteration in pharmacokinetics of mannitol in cirrhotic patients with tense ascites. El Okbi S, El Khattib A, Kamal SM, El Marsafi A, Madwar MA. Al
Azhar Journal of Pharamaceutical Sciences 1994; 13: 49-58.
60. The role of Doppler ultrasound in hepatocellular carcinoma. Kamal SM, Omar HO, Fawzy RA. Al Azhar Medical Journal 1994; 16: 82-87.
61. Diagnostic significance of IgM antibody detection in typhoid by a new modification in Widal test. Kamal SM, Abdel Wahab MF, El Okbi S, Farag D, El Saghir M, Sultan Y, Mansour H. Journal of Tropical Medicine (JTM) 1994; 3 : 133-138.
62. A flowcytometric study of gastric nuclear DNA content in gastritis. El Wakil RM, Kamal SM, Fawzy RA, Massoud MA. Journal of Tropical
Medicine 1994; 3: 125-132.
63. Correlation between ultrasonography, alpha feto protein and pathology in hepatocellular carcinoma. Shaker MK, Kamal SM, El Tawil MA, Talkhan
HS. Journal of Immunology 1995; 1: 93-96.
1. AlArjani A, Nasseef MT, Kamal SM, Rao BVS, Mahmud M, Uddin MApplication of Mathematical Modeling in Prediction of COVID-19 Transmission Dynamics.
. Arab J Sci Eng. 2022 Jan 7:1-24. doi: 10.1007/s13369-021-06419-4.
2. Kamal S, Naghib MM, Al Zahrani J, Hassan H, Moawad K, Arrahman O. Influence of Nutrition on Disease Severity and Health-related Quality of Life in Adults with Sickle Cell Disease: A Prospective Study Mediterr J Hematol Infect Dis. 2021 Jan 1;13(1):e2021007. doi: 10.4084/MJHID.2021.007. eCollection 2021.
3. Kamal S, Abdelhakam S, Ghoraba D, Mohsen MA, Salam AA, Hassan H, Nabeigh L. The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study. Mediterr J Hematol Infect Dis. 2019 Nov 1;11(1):e2019060.
4. Sanaa Kamal, Sara Mahmoud Abdelhakam, Dhalia Ghoraba, Yasmin Massoud, Kareem Abdel Aziz, Amgad H Kamel, Tamer Hafez. The Frequency, Clinical Patterns, Nutritional Status and Health Related Quality of Life in Adults with Gilbert’s Syndrome: A Prospective Longitudinal Study. Journal of Clinical Gastroenterology, 2018 (in press).
5. Sanaa Kamal, Khaled K Aldossari, Dhalia Ghoraba, Sara Mahmoud Abdelhakam, Amgad H Kamel, Mohamad Bedewi, Leila Nabegh, Khaled Bahnasy, Tamer Hafez. Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and nonalcoholic fatty liver disease in adults: a large prospective longitudinal study. BMJ Gastroenterology 2018, 5:e000150. doi:10.1136/bmjgast-2017-000150
6. Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, Kamal F, Howden CW, Stave C, Nair S, Satapathy SK, Ahmed A.Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017 Oct;112(10):1495-1505.
7. Kamal S.M. , Kassim S.K., Shehata H.H., Salib M.M, Nabegh. L.M.. Evaluation of serum fibrotic markers; CTGF, IL-17and TGF-β1 versus liver biopsy for detection of hepatic fibrosis in Egyptian patients with chronic hepatitis C. ,MetGene, Volume 13, September 2017, :63-69
8. Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, Bahnasy K, Hassan H, Ghoraba D The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2015 Aug;42(3):307-18.
9 Kamal SM. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med. 2014 Jun 24;6:61-77.
10. Sanaa Kama, Samar Kassem, Amany Ahmed, Sara Mahmoud, Dahlia Ghoraba, Iman El Gohary, Khaled Bahnasy, Tamer Hafez, Iman Fathelbab, Maha Sobhy, Hoda Mansour ,Host and Viral Determinants of the Outcome of Exposure to HCV Infection Genotype 4: A Large Longitudinal . American Journal of Gastroenterology. 2014 Feb;109(2):199-21
11.. . Sanaa Kamal. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Sanaa Kamal. Hepatic Medicine: Evidence and Research. May, 2014
12; T
Hepatitis C virus genotype 4 therapy: progress and challenges.
Kamal SM. Liver Int. 2011 Jan;31 Suppl 1:45-52. doi: 10.1111/j.1478-3231.2010.02385.x.
14. Cyanocobalamin, vitamin D and Ferritin Levels in Saudi Patients with Non-alcoholic Liver Disease (NAFLD) Sanaa M. Kamal, Waheed M. A. Al-Harizi, Magdy Saad, Mohamed A. Bedewi. Liver International accepted May ,2017
13. Impact of Helicobacter Pylori eradication on Vitamin B12 and Vitamin D levels. Sanaa M. Kamal, Waheed Al Harizi, Shafqat Qamar, Magdy Saad. Helicobacter accepted May ,2017
14. Comparison of immunogenicity and safety of Engerix B and Twinrix vaccine in aSaudi Population. Sanaa M. Kamal, Abdul Rahaman Aldiab, Shafqat Qamar, Waheed Al Harizi. Gut. accepted May ,2014
15. Pegylated Interferon α-2a and Pegylated Interferon α-2b plus Ribavirin in Chronic HCV Genotype 4: A randomized trial and quality of life analysis" Sanaa Kamal, Amany Ibrahiem, Tamer Hafez; Isa Obedan I; Sara Mahmoud, Mona Motaoe, Dahlia Ghoraba, Ahmed Abdel Aziz. Liver Int. 2011;31(3):401-411. 6.
16. Hepatitis C virus genotype 4 therapy: progress and challenges Kamal SM. Liver Int. 2011 J;31 Suppl 1:45-52
17. Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine. Sanaa Kamal. Current
Pharmacogenomics and Personalized Medicine 2011. 8 (5): 333-342
12. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P Liver Int. 2010 Mar;30(3):342-55
13. Pegylated Interferon α-2a and Pegylated Interferon α-2b plus Ribavirin in Chronic HCV Genotype 4: A randomized trial and quality of life analysis" Sanaa Kamal, Amany Ibrahiem, Tamer Hafez; Isa Obedan I; Sara Mahmoud, Mona Motaoe, Dahlia Ghoraba, Ahmed Abdel Aziz. Liver Int. 2011;31(3):401-411.
14. Hepatitis C virus genotype 4 therapy: progress and challenges Kamal SM. Liver Int. 2011 J;31 Suppl 1:45-52
15. Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine. Sanaa Kamal. Current
Pharmacogenomics and Personalized Medicine 2011. 8 (5): 333-342
16. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Antaki N, Craxi A, Kamal S, Moucari R, Van der
Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P Liver Int. 2010 Mar;30(3):342-55
17. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Sanaa Kamal. Liver International, Liver Int. 2009 Jan;29
Suppl 1:39-48
18. Acute Hepatitis C. A systematic review. Sanaa Kamal. Am J Gastroenterol. 2008 May;103(5):1283-97
19. Hepatitis C genotype 4: What we know and what we don’t yet know. Sanaa Kamal and Imad Nasser. Hepatology. 2008 Jan 28;47(4):1371-1383.
20. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response.
Kamal S; Kamary S; Shardell M; Nasser I; Hashem M; Muhamadi M; Moustafa A; Sayed K; Abdel Hakem S; Ibrahim A; Mansour H; Abddelaziz M. Hepatology. 2007 Dec;46(6):1732-40.
21. Acute hepatitis C: Prospects and challenges. Kamal SM.. World J Gastroenterol. 2007 Dec 28;13(48):6455-7.
22. Genotypic variation around the world: Is hepatitis C evolving? Sanaa M. Kamal, Current Hepatitis Reports 2006
23. Improving Outcome in Patients with Hepatitis C Virus Genotype 4. Sanaa M. Kamal. Am J Gastroenterol. 2007 Nov;102(11):2582-8.
Epub 2007 Sep 26
24. Progression of Fibrosis in Chronic Hepatitis C with and without Schistosomiasis: Correlation to Serum Fibrosis Markers and Cytokines..Kamal S, Turner B, Bianch L; Tawil A, Ahmed N ,Mahmoud M ; Koziel M;, Afdhal N, Hepatology, Vol. 43, No. 4, 2006
25. Peg-interferon alfa-2b for the treatment of patients with acute hepatitis C: Impact of onset of therapy on sustained virologic response Kamal S, El
Tawil A., EL Naggar K, Rasenack J, Hakam S, Saleh W, EL Fouly, Ismail A, Abdel Aziz A, Madwar M, Koziel M, Afdhal N.Gastroenterology
2006;130:632–638
26. Duration of Peg-interferon alfa-2b in acute hepatitis C: A randomized clinical trial.S Kamal, K El Naggar, J Chen, M Moniem, I Gohary, N Afdhal; Jens Rasenack. Hepatology, HEPATOLOGY, Vol. 43, No. 5, 2006
27. Immune modulation by helminthic infections: worms and viral infections. S. M. K Kamal and E Khalifa.. Parasite Immunology :365-3024.2006.
28. Peginterferon-alpha 2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virologic response. Kamal S, El Tawil A., Nakano T, Rasenack J, Hakam S, Saleh W, Ismail A, Abdel Aziz A, Madwar M. GUT, 2005 Gut 54 (6): 858-866
29. Cellular Immune Responses in Seronegative Sexual Contacts of Acute Hepatitis C Patients . Sanaa M Kamal , Mahmoud Massoud, Jens Rasenack,
, ,
Thomas Peters, Camilla S. Graham, Qi He Ahmed Al Tawil Leonardo Bianchi, Tatsarouni Nakano, Betty Robertson, Alaa Ismail Margaret James
,
.
Koziel J Virol. 2004 Nov;78(22):12252-8.
*
30. Peginterferon Alpha Therapy in Acute Hepatitis C Prevents Chronicity and Enhances Hepatitis C Virus-Specific T-cell Responses. Sanaa M Kamal ,
, ,
Alaa Ismail, Camilla S Graham, Qi He, Jens W Rasenack Thomas Peters Ahmed A Tawil, Jutta J Fehr Khalifa El Sayed Khalifa, Mahmoud M
.
Massoud, Margaret J Koziel
Hepatology. 2004 Jun;39(6):1721-31.
+
31. Kinetics of intrahepatic hepatitis C-virus specific CD4
T cell responses in patients coinfected with S.mansoni: Relation to liver fibrosis progression.
,
Sanaa M Kamal, Camilla A Graham, Qi He, Leonardo Bianchi, Jens W Rasenack Ahmed A Tawil Khalifa A Khalifa, Mahmoud M Massoud, Alaa
Ismail, Margaret J Koziel. Journal of Infectious Diseases The Journal of Infectious Diseases 2004; 189:1140–50
32. Peginterferon Alone or in Combination with Ribavirin Enhances HCV Specific CD4+ T Helper 1 Responses in Patients with Chronic Hepatitis C.
Sanaa M. Kamal; Jutta Fehr, Bernd Roesler, Thomas Peters, Jens W. Rasenack. Gastroenterology 2002; 123 (4)
33. Acute Hepatitis C With and Without Schistosomiasis: Correlation with Hepatitis C Specific CD4+ T Cell and Cytokine Response. . Kamal S, Rasenack J, Bianchi L, Al Tawil A, Mansour H, Khalifa K, Peters T, Koziel M. Gastroenterology. 2001 Sep;121(3):646-56.
34. Specific cellular immune response and cytokine profile in patients with chronic hepatitis C co-infected with schistosomiasis. Kamal SM, Bianchi L, El
Tawil A, Koziel M, Khalifa K, Peters T, Rasenack J. Journal of Infectious Diseases 2001; 184:972-982
35. Interferon therapy in patients with hepatitis C and schistosomiasis. Kamal SM, Madwar MA, Peters T, Fawzy R, , Rasenack J. J Hepatol. 2000 Jan;
32(1):172-4.
36. Clinical, Virological, Histological Featurres and Long Follow-up of Patients with Hepatitis C Co-infected with Schistosomiasis. Kamal SM, Madwar
MA, Bianchi L, Peters T, Fawzy R, El Tawil A, Rasenack J. Liver. 2000 Jul; 20(4):281-9
37. The diagnostic significance of ascitic fluid ferritin. Kamal SM, Farrag D, Skr MA, Abdel Ghany EA. Egyptian Journal of Medical Laboratory Science
1999; 4: 9-16.
38. The effect of diuresis on the opsonic activity of cirrhotic patients. Abdel Moneif W, Kamal SM, Sherif H. Egypt J Med Lab Sci 1999; 4: 39-44.
39. Renal Hemodynamics alterations in hepatic cirrhosis evaluated by duplex Doppler ultrasound. Kamal SM, Omar OH, El Naggar MK. Journal of
Hepatology, Gastroenterology and Infectious Diseases (JHGID) 1996; 4 (3): 79-85.
40. The diagnostic significance of ascitic fluid ferritin. Kamal SM, Farrag D, Skr MA, Abdel Ghany EA. Egyptian Journal of Medical Laboratory Science
1995; 4: 9-16.
41. The effect of diuresis on the opsonic activity of cirrhotic patients. Abdel Moneif W, Kamal SM, Sherif H. Egypt J Med Lab Sci 1995; 4: 39-44.
42. Allergic manifestations of giardiasis. Kamal SM, Abbass M, El Sherif H. Journal of Tropical Medicine 1996, 4: 55-60.
43 Cryoglobulinemia in chronic viral hepatitis. Kamal SM, Ezzat A, Shaker A, El Nokaly F. Egypt J Med Lab Sci 1996; 5 (1): 21-28.
44. Parasitological and bacteriological studies in recurrent diarrhoea in patients with chronic liver diseases. Younes TA, Hussein MM, Kamal SM, Mahmoud DM, Metwaly SF. J Egypt Soc Parasitol. 1996 Dec;26(3):697-708.
45. Colorectal cancer in Egyptian patients under 40 years of age. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S, Hammam HM, el- Hattab OH, Kamal SM, Soliman AG, Dorgham LA, McPherson RS, Beasley RP. Int J Cancer. 1997 Mar 28;71(1):26-30.
46. Correlation between p53 expression and the clinicopathologic and DNA ploidy patterns in different forms of colitis in Egypt. Massoud MA, Kamal
st
SM, Eissa S, Khalifa EK. Ismail N. Journal of Gastrointestinal tract in the 21
Century 1997; 2 (2):62-69.
47. The prevalence of hepatitis E virus among acute sporadic hepatitis patients in Cairo. Madwar MA, Kamal SM, Ezzat A, Talkhan H, Sultan Y. Journal of Immunology 1997; 4: 38-44.
48. Renal Hemodynamics alterations in hepatic cirrhosis evaluated by duplex Doppler ultrasound. Kamal SM, Omar OH, El Naggar MK. Journal of
Hepatology, Gastroenterology and Infectious Diseases (JHGID) 1998; 4 (3): 79-85.
49. Serum nitrite and nitrate in cirrhotic patients: Relation to endotoxemia and cytokines. Kamal SM, Abdel Monseif W, Nessim N, Nooh O, Madwar
MA. Journal of Hepatology, Gastroenterology and Infectious Diseases (JHGID) 1998; 4 (4): 39- 48.
50. Lymphadenopathies of undetermined etiology in Egypt. Abdel Wahab MF, Saif El Din, Kamal SM, El Tawil AA, Azab ME. Egyptian Medical
Journal (EMJ) 1992; 6 (2): 121-127
57. The role of Epestein Barr virus in Hodgkin Disease. El Okbi SA, Kamal SM, Talkhan HS. Journal of Immunology 1993; 1: 78-81.
58. Helicobacter pylori infection in gastric malignancy. Abdel Monseif W, Kamal SM, Azzazy H, Ismail S, Ezz El Din W. Menoufia Med. Journal 1993;
6: 193-196.
59. Alteration in pharmacokinetics of mannitol in cirrhotic patients with tense ascites. El Okbi S, El Khattib A, Kamal SM, El Marsafi A, Madwar MA. Al
Azhar Journal of Pharamaceutical Sciences 1994; 13: 49-58.
60. The role of Doppler ultrasound in hepatocellular carcinoma. Kamal SM, Omar HO, Fawzy RA. Al Azhar Medical Journal 1994; 16: 82-87.
61. Diagnostic significance of IgM antibody detection in typhoid by a new modification in Widal test. Kamal SM, Abdel Wahab MF, El Okbi S, Farag D, El Saghir M, Sultan Y, Mansour H. Journal of Tropical Medicine (JTM) 1994; 3 : 133-138.
62. A flowcytometric study of gastric nuclear DNA content in gastritis. El Wakil RM, Kamal SM, Fawzy RA, Massoud MA. Journal of Tropical
Medicine 1994; 3: 125-132.
63. Correlation between ultrasonography, alpha feto protein and pathology in hepatocellular carcinoma. Shaker MK, Kamal SM, El Tawil MA, Talkhan
HS. Journal of Immunology 1995; 1: 93-96.

Prof.Sanaa Moharram Moharram Kamal

Education

Research Interests

Experience

Responsibilities

Publications

Contact the university leaders

Administration of Public Relations and Media

Social

Faculty Members

Prof.Sanaa Moharram Moharram Kamal

Education

Research Interests

Experience

Responsibilities

Publications

Administration of Public Relations and Media